Gloomy outlook for US diagnostic imaging agents
This article was originally published in Clinica
Executive Summary
The mood was bleak at the 10th annual symposium on Economics of Diagnostic Imaging, reports Clinica's Washington correspondent, Duffy Miller. While low osmolality (non-ionic) contrast agents (LOCA) are vastly safer than the older ionic contrast agents, they are also more expensive. "With the economic restraints that are being placed on the medical system in the US, there will be increasing pressure from many sources for reconversion to the less expensive ionic agents," Dr Mark Mishkin warned fellow radiologists at the Washington meeting on October 26th.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.